Navigation Links
Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002)
Date:2/27/2008

TOKYO, Feb. 27 /PRNewswire/ -- Kyowa Hakko Kogyo Co., Ltd. (President: Dr. Yuzuru Matsuda) announced that Kyowa Pharmaceutical, Inc. (New Jersey, United States), its wholly owned U.S. subsidiary, received on February 25, 2008 (local time) a Not approvable letter from the U.S. Food and Drug Administration (FDA) for istradefylline (KW-6002), its investigational drug for the treatment of Parkinson's disease.

In the not approvable letter FDA expressed concern if the efficacy findings support clinical utility of istradefylline (KW-6002). FDA requested an overall summary of nonclinical mineralization findings. Additionally, FDA asked for clinical pharmacology follow-up information as a Phase 4 commitment.

After closely examining the FDA's response, Kyowa Hakko will work closely with FDA and conduct a comprehensive discussion to determine a path forward for istradefylline (KW-6002).

Istradefylline (KW-6002) has a novel mechanism of action that antagonizes the adenosine A2A receptor. It has been under FDA review as adjunctive therapy to levodopa/carbidopa for the treatment of idiopathic Parkinson's disease to improve motor function in patients who experience motor response complications.

Kyowa Hakko is a biotechnology-based company focused on two businesses: pharmaceutical operations engaged in the research and development, manufacturing, and marketing of prescription drugs; and bio-chemical operations that handle a variety of products such as amino acids, nucleic acids, and nutritional supplements/healthcare products. Its pharmaceutical business places emphasis on research and development in the fields of oncology, allergy, and the central nervous system. In Japan, Kyowa Hakko is marketing medications for a wide range of diseases, including allergy, hypertension, angina pectoris, and cancer. With the aim of penetrating the global market, Kyowa Hakko has overseas development bases in the U.S. (Kyowa Pharmaceutical, Inc. and BioWa, Inc.) an
'/>"/>

SOURCE Kyowa Hakko Kogyo Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SAN CARLOS, Calif. , Aug. 4, 2015 /PRNewswire/ ... non-invasive genetic testing and the analysis of circulating cell-free ... its second quarter ended June 30, 2015 after the ... a conference call and webcast at 1:30 p.m. PT ... activities and financial outlook.Event:Natera,s Second Quarter 2015 Results Conference ...
(Date:8/3/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast ... 2015 on Monday, August 10, 2015 at 4:30 p.m. ... and chief executive officer, will lead the call. On ... for the second quarter 2015. The call ... Halozyme,s corporate website and a recording will be made ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... consumer of benzene. Benzene is processed to get such derivatives as ethylbenzene, a ... derivatives are principally used within the automotive industry for the production of tyres ...
(Date:8/3/2015)... , August 3, 2015 E-QURE ... commercialization of its Bio-electrical Signal Therapy device ("BST Device"), ... of hard to heal chronic wounds, today announced that ... Chemipal, an Israeli distributor specializing in medical devices, for ... Chemipal is a 70 years old, sales, marketing ...
Breaking Biology Technology:Natera to Release Second Quarter 2015 Results on August 12, 2015 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3
... TE 70, TE 77, TE 70 PWR, TE 77 PWR , ... transfer results using low current and voltage with a minimal amount of buffer. ... with and without built-in power supplies to give maximum flexibility , ... from polyacrylamide gels in less than 1 h , ...
... , ... DIGE Imager • fluorescent Western blotting • multiplex detection • dynamic ... The Ettan™ DIGE Imager is fully compatible with ... and dynamic range as the Typhoon™ scanner. Similar results are also ...
... , Key words: ... Beads, , ... pituitary and are processed into three major peptide hormone fragments: adrenocorticotrophin ... hormones are known to activate the MC 5 (melanocortin subtype ...
Cached Biology Technology:ECL Semi-dry Blotters 2Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 2Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 3Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 4Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 5Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 6Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 7Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 8The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 2The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 3The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 4The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 5
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... 29, 2013) Pregnant women with mid to high ... are at risk for having babies with reduced fetal ... in Gastroenterology , the official journal of the ... most commonly found in patients with celiac disease. ...
... April 29, 2013 Research and ... "Gesture Recognition & Touchless Sensing Market (2013 - ... Product (Biometric, Sanitary Equipment); Application (Healthcare, Consumer Electronics, ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ...
... an effective herbal remedy useful for weight control and helping ... ascertain whether green tea truly has this potential, Jae-Hyung Park ... in the Republic of Korea conducted a study, now published ... The active constituents of green tea, which have been ...
Cached Biology News:Pregnant women with high celiac disease antibodies are at risk for low birth weight babies 2Gesture Recognition & Touchless Sensing Market (2013 - 2018): By Technology, Product, Application and Geography 2Gesture Recognition & Touchless Sensing Market (2013 - 2018): By Technology, Product, Application and Geography 3Will green tea help you lose weight? 2
ID clarifier: Without ethidium bromide...
... Biotin Streptavidin-HRP Systems provide rapid, precise ... antigens in frozen or paraffin-embedded tissue, ... systems also facilitate double or triple ... performed simultaneously with primary antibodies of ...
...
... covers can be used with ... covers for stacking of covered ... for use with automated systems ... and non-ridged, are available for ...
Biology Products: